How I treat elderly patients with diffuse large B-cell lymphomaPFREUNDSCHUH, Michael.Blood. 2010, Vol 116, Num 24, pp 5103-5110, issn 0006-4971, 8 p.Article

Rituximab in High-Grade LymphomaZWICK, Carsten; MURAWSKI, Niels; PFREUNDSCHUH, Michael et al.Seminars in hematology. 2010, Vol 47, Num 2, pp 148-155, issn 0037-1963, 8 p.Article

Der Zeitfaktor in der Onkologie: Spielt die Gesamtbehandlungszeit in der Chemotherapie eine Rolle? = The role of treatment duration in chemotherapy regimens for the treatment of malignant diseasesTRÜMPER, Lorenz; PFREUNDSCHUH, Michael.Strahlentherapie und Onkologie. 2000, Vol 176, Num 10, pp 466-471, issn 0179-7158Conference Paper

Rituximab for the treatment of diffuse large B-cell lymphomasHELD, Gerhard; PÖSCHEL, Viola; PFREUNDSCHUH, Michael et al.Expert review of anticancer therapy. 2006, Vol 6, Num 8, pp 1175-1186, issn 1473-7140, 12 p.Article

Lymphoma 2000: the first International Symposium on Biology and Treatment of Agressive Lymphomas: the Stagnation seems to be overSCHMITS, Rudolf; TRüMPER, Lorenz; PFREUNDSCHUH, Michael et al.Annals of hematology. Supplement. 2001, Vol 80, Num 3, issn 0945-8077, 166 p.Conference Proceedings

Therapeutic strategies for aggressive lymphomasPFREUNDSCHUH, Michael.European journal of cancer. Supplement (1990). 2003, Vol 1, Num 6, pp 31-40, issn 1359-6349, 10 p.Conference Paper

CNS events in elderly patients with aggressive lymphoma treated with modem chemotherapy (CHOP-14) with or without rituximab : an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)BOEHME, Volkmar; SCHMITZ, Norbert; ZEYNALOVA, Samira et al.Blood. 2009, Vol 113, Num 17, pp 3896-3902, issn 0006-4971, 7 p.Article

Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell LymphomaHELD, Gerhard; MURAWSKI, Niels; SCHMITZ, Norbert et al.Journal of clinical oncology. 2014, Vol 32, Num 11, pp 1112-1118, issn 0732-183X, 7 p.Article

Progranulin antibodies in autoimmune diseasesTHURNER, Lorenz; PREUSS, Klaus-Dieter; PASQUALI, Jean-Louis et al.Journal of autoimmunity (Print). 2013, Vol 42, pp 29-38, issn 0896-8411, 10 p.Article

MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomasROEHLE, Anja; HOEFIG, Kai P; MATOLCSY, Andras et al.British journal of haematology. 2008, Vol 142, Num 5, pp 732-744, issn 0007-1048, 13 p.Article

Dmg treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. CommentaryGUILHOT, Francois; HEHLMANN, Rüdiger; REITER, Andreas et al.Blood. 2007, Vol 109, Num 11, issn 0006-4971, 4592, 4686-4692 [8 p.]Article

Expression of serologically identified tumor antigens in acute leukemiasNIEMEYER, Philipp; TÜRECI, Özlem; EBERLE, Thomas et al.Leukemia research. 2003, Vol 27, Num 7, pp 655-660, issn 0145-2126, 6 p.Article

Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: Mutated p21 ras oncogene in pancreatic carcinoma as a modelKUBUSCHOK, Boris; SCHMITS, Rudolf; HARTMANN, Frank et al.Human gene therapy. 2002, Vol 13, Num 7, pp 815-827, issn 1043-0342Article

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trialDREGER, Peter; DÖHNER, Hartmut; DÜHRSEN, Ulrich et al.Blood. 2012, Vol 119, Num 21, pp 4851-4859, issn 0006-4971, 9 p.Article

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCLMÜLLER, Carsten; MURAWSKI, Niels; METZNER, Bernd et al.Blood. 2012, Vol 119, Num 14, pp 3276-3284, issn 0006-4971, 9 p.Article

High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's LymphomaMORSCHHAUSER, Franck; KRAEBER-BODERE, Françoise; NAUMANN, Ralph et al.Journal of clinical oncology. 2010, Vol 28, Num 23, pp 3709-3716, issn 0732-183X, 8 p.Article

Effects of Physical Exercise on Myocardial Telomere-Regulating Proteins, Survival Pathways, and ApoptosisWERNER, Christian; HANHOUN, Milad; HAENDELER, Judith et al.Journal of the American College of Cardiology. 2008, Vol 52, Num 6, pp 470-482, issn 0735-1097, 13 p.Article

Mitofilin and titin as target antigens in melanoma-associated retinopathyPFÖHLER, Claudia; PREUSS, Klaus-Dieter; TILGEN, Wolfgang et al.International journal of cancer. 2007, Vol 120, Num 4, pp 788-795, issn 0020-7136, 8 p.Article

Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (MegaCHOEP) and autologous stem cell transplantation : Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphomaSCHMITZ, Nobert; KLOESS, Marita; GLASS, Bertram et al.Cancer. 2006, Vol 106, Num 1, pp 136-145, issn 0008-543X, 10 p.Article

Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypesNEUMANN, Frank; WAGNER, Claudia; KUBUSCHOK, Boris et al.Cancer immunology and immunotherapy. 2004, Vol 53, Num 7, pp 589-599, issn 0340-7004, 11 p.Article

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLPFREUNDSCHUH, Michael; TRÜMPER, Lorenz; SCHMITZ, Norbert et al.Blood. 2004, Vol 104, Num 3, pp 626-633, issn 0006-4971, 8 p.Article

Hodgkin and Reed-Sternberg cell-associated autoantigen CLIP-170/restin is a marker for dendritic cells and is involved in the trafficking of macropinosomes to the cytoskeleton, supporting a function-based concept of Hodgkin and Reed-Sternberg cellsSAHIN, Ugur; NEUMANN, Frank; TÜRECI, Özlem et al.Blood. 2002, Vol 100, Num 12, pp 4139-4145, issn 0006-4971, 7 p.Article

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo systemRENNER, Christoph; STEHLE, Ingo; SCOTT, Andrew M et al.Cancer immunology and immunotherapy. 2001, Vol 50, Num 2, pp 102-108, issn 0340-7004Article

Chromosomal localization and promoter analysis of the adenomatous polyposis coli binding protein RP1WADLE, Andreas; THIEL, Gerald; MISCHO, Axel et al.Oncogene (Basingstoke). 2001, Vol 20, Num 41, pp 5920-5929, issn 0950-9232Article

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVHEHLMANN, Rüdiger; MÜLLER, Martin C; SCHNITTGER, Susanne et al.Journal of clinical oncology. 2014, Vol 32, Num 5, pp 415-423, issn 0732-183X, 9 p.Article